ClinicalTrials.gg
CompletedNCT04998201MUIRUpdated Apr 14, 2026Results posted

Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia

A Phase 2 interventional study of ARO-APOC3 and Placebo in Mixed Dyslipidemia, sponsored by Arrowhead Pharmaceuticals. Completed at 30 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-14.

Sponsored by Arrowhead Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
353
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 349 studies in Dyslipidemias with a site in United States — 23 open to participants now, 34 under way, 6 of them phase 3. Dyslipidemias · United States.

Enrollment
78th of 316
353 · median 105
Started
2021
with 9 others
Phase 2
66 of 349
2 open now
Registered
283rd of 349
by date

Among the 349 studies in Dyslipidemias with a site in United States, this one is the 78th largest by enrollment of the 316 interventional ones that give a count, is one of 10 that started in 2021, is one of 66 in phase 2, and was the 283rd registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

23 of the 349 studies in Dyslipidemias with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 349 studies in Dyslipidemias with a site in United States, or all of them as a file.
02

Study summary

Participants who have met all protocol eligibility criteria will be randomly assigned to treatment (ARO-APOC3 or placebo) in a double-blind fashion and will be evaluated for safety and efficacy over 48 weeks. Participants will be counseled to remain on a specified diet throughout the study, as recommended by the Investigator in accordance with local standards of care. After week 48, participants will be eligible and invited to consent and continue in an open-label extension study. All placebo participants who opt to continue will switch to active drug (ARO-APOC3) during the extension study.

03

Conditions studied

  • Mixed Dyslipidemia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

Based on medical history, prior evidence of triglycerides (TG) ≥ 150 milligrams (mg)/deciliter (dL) and ≤ 499 mg/dL

  • Fasting levels at Screening of non-high-density lipoprotein cholesterol (non-HDL-C) ≥ 100 mg/dL or low-density lipoprotein cholesterol (LDL-C) ≥ 70 mg/dL after at least 2 weeks of stable diet and 4 weeks on stable optimal statin therapy
  • Mean fasting TG ≥ 150 mg/dL and ≤ 499 mg/dL during Screening collected at two separate and consecutive visits and at least 7 days apart and not more than 17 days apart
  • Willing to follow diet counseling as per Investigator judgment based on local standard of care
  • Participants of (males \& females) must use highly effective during the study and for at least 24 weeks following the last dose of study medication. Males must not donate sperm and females must not donate eggs during the study and for at least 24 weeks following the last dose of study medication.
  • Women of childbearing potential must have a negative pregnancy test at Screening and cannot be breastfeeding
  • Women of childbearing potential on hormonal contraceptives must be stable on the medication for ≥ 2 menstrual cycles prior to Day 1
  • Willing to provide written and to comply with study requirements

Key Exclusion Criteria:

  • Current use or use within 365 days from Day 1 of any hepatocyte targeted short interfering RNA oligonucleotides (siRNA) or antisense oligonucleotide molecule
  • Active pancreatitis within 12 weeks prior to Day 1
  • Any planned bariatric surgery or similar procedures to induce weight loss from consent through end of study
  • Acute coronary syndrome event within 24 weeks of Day 1
  • History of major surgery within 12 weeks of Day 1 or planned major surgery during the study
  • Planned coronary intervention (such as, stent placement or heart bypass) during the study
  • (NYHA) Class II, III or IV heart failure or last known of \<30%
  • Uncontrolled hypertension
  • Known history of (HIV) infection, seropositive for virus (HBV), seropositive for virus (HCV)
  • Uncontrolled hypothyroidism or hyperthyroidism
  • Hemorrhagic stroke within 24 weeks of Day 1
  • History of bleeding diathesis or coagulopathy
  • Current diagnosis of nephrotic syndrome
  • Systemic use of or anabolic steroids within 4 weeks prior to Day 1 or planned use during the study
  • within the last 2 years prior to date of consent requiring systemic treatment (some exceptions apply)

Note: Additional inclusion/exclusion criteria may apply per protocol

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
353 participants (actual)

Study arms

  • Experimental
    ARO-APOC3 10 mg Q12W

    ARO-APOC3 10 milligrams (mg) subcutaneous (SC) injection on Day 1 and Week 12 (Q12W) for a total of 2 injections

    Drug: ARO-APOC3

  • Experimental
    ARO-APOC3 25 mg Q12W

    ARO-APOC3 25 mg SC injection on Day 1 and Week 12 (Q12W) for a total of 2 injections

    Drug: ARO-APOC3

  • Experimental
    ARO-APOC3 50 mg Q12W

    ARO-APOC3 50 mg SC injection on Day 1 and Week 12 (Q12W) for a total of 2 injections

    Drug: ARO-APOC3

  • Experimental
    ARO-APOC3 50 mg Q24W

    ARO-APOC3 50 mg SC injection on Day 1 and Week 24 (Q24W) for a total of 2 injections

    Drug: ARO-APOC3

  • Placebo comparator
    Placebo

    Volume-matched placebo SC injection on Day 1 and Week 12 for a total of 2 injections

    Drug: Placebo

Interventions

  • ARO-APOC3 Injection

    Also known as: Plozasiran

  • DrugPlacebo

    Sterile Normal Saline (0.9% NaCl)

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline at Week 24 in Fasting TG

    Least square (LS) mean and standard error (SE) were calculated using mixed model repeated measures (MMRM) which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Percent Change From Baseline Over Time Through Week 48 in Fasting TG

    LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 36, 48/early termination (ET)

  2. Percent Change From Baseline at Week 24 in Apolipoprotein (Apo)C-III

    LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.

    Time frame: Baseline, Week 24

  3. Percent Change From Baseline Over Time Through Week 48 in ApoC-III

    LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 36, 48/ET

  4. Percent Change From Baseline at Week 24 in Fasting Non-High-Density Lipoprotein Cholesterol (Non-HDL-C)

    LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.

    Time frame: Baseline, Week 24

  5. Percent Change From Baseline Over Time Through Week 48 in Fasting Non-HDL-C

    LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 36, 48/ET

  6. Percent Change From Baseline at Week 24 in Fasting High-Density Lipoprotein Cholesterol (HDL-C)

    LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.

    Time frame: Baseline, Week 24

  7. Percent Change From Baseline Over Time Through Week 48 in Fasting HDL-C

    LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 36, 48/ET

  8. Percent Change From Baseline at Week 24 in Fasting Total Apolipoprotein B (ApoB)

    LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.

    Time frame: Baseline, Week 24

  9. Percent Change From Baseline Over Time Through Week 48 in Fasting Total ApoB

    LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 36, 48/ET

  10. Percent Change From Baseline at Week 24 in Fasting Low-Density Lipoprotein-Cholesterol (LDL-C)

    LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.

    Time frame: Baseline, Week 24

  11. Percent Change From Baseline Over Time Through Week 48 in Fasting LDL-C

    LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 36, 48/ET

  12. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence, which did not necessarily have to have a causal relationship with this treatment. A serious AE (SAE) was an AE that: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of an existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; or was a medically important event or reaction. TEAEs were AEs that occurred following study drug administration or a pre-existing condition exacerbated following study drug administration.

    Time frame: Up to Week 48

07

Results

Posted Feb 24, 2026

Participant flow

Participant flow — Overall Study
MilestonePlaceboARO-APOC3 10 mg Q12WARO-APOC3 25 mg Q12WARO-APOC3 50 mg Q12WARO-APOC3 50 mg Q24W
Started8767676666
Received at least 1 dose of study drug8767676666
Completed7860646161
Not completed97355
Withdrew: Withdrawal by subject33112
Withdrew: Physician decision31000
Withdrew: Death00121
Withdrew: Adverse event01001
Withdrew: Lost to follow-up22110
Withdrew: Protocol deviation10010
Withdrew: Other, not specified00001

Outcome measures

PrimaryPercent Change From Baseline at Week 24 in Fasting TG

Least square (LS) mean and standard error (SE) were calculated using mixed model repeated measures (MMRM) which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · percentage change
Percent Change From Baseline at Week 24 in Fasting TG
percentage changePlaceboARO-APOC3 10 mg Q12WARO-APOC3 25 mg Q12WARO-APOC3 50 mg Q12WARO-APOC3 50 mg Q24W
Percent Change From Baseline at Week 24 in Fasting TG-1.7 ± 3.07-51.5 ± 3.54-57.7 ± 3.49-64.1 ± 3.51-45.9 ± 3.52
Statistical analysis
  • Placebo vs ARO-APOC3 10 mg Q12W · Mixed Models Analysis · p = <0.0001 (MMRM model included treatment arm, study visit, and baseline value as model terms. The model also included treatment by visit and treatment by baseline as interaction terms.) · Ls mean difference: -49.8 · 95% CI -59.0 to -40.6
  • Placebo vs ARO-APOC3 25 mg Q12W · Mixed Models Analysis · p = <0.0001 (MMRM model included treatment arm, study visit, and baseline value as model terms. The model also included treatment by visit and treatment by baseline as interaction terms.) · Ls mean difference: -56.0 · 95% CI -65.1 to -46.8
  • Placebo vs ARO-APOC3 50 mg Q12W · Mixed Models Analysis · p = <0.0001 (MMRM model included treatment arm, study visit, and baseline value as model terms. The model also included treatment by visit and treatment by baseline as interaction terms.) · Ls mean difference: -62.4 · 95% CI -71.5 to -53.2
  • Placebo vs ARO-APOC3 50 mg Q24W · Mixed Models Analysis · p = <0.0001 (MMRM model included treatment arm, study visit, and baseline value as model terms. The model also included treatment by visit and treatment by baseline as interaction terms.) · Ls mean difference: -44.2 · 95% CI -53.4 to -35.0
SecondaryPercent Change From Baseline Over Time Through Week 48 in Fasting TG

LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 36, 48/early termination (ET)
Reported as:
Least squares mean · percentage change
Percent Change From Baseline Over Time Through Week 48 in Fasting TG
percentage changePlaceboARO-APOC3 10 mg Q12WARO-APOC3 25 mg Q12WARO-APOC3 50 mg Q12WARO-APOC3 50 mg Q24W
Change at Week 4-0.5 ± 2.77-51.4 ± 3.21-61.5 ± 3.14-66.4 ± 3.20-62.5 ± 3.19
Change at Week 8-0.4 ± 2.45-48.6 ± 2.78-58.1 ± 2.77-65.0 ± 2.78-59.7 ± 2.78
Change at Week 12-0.1 ± 3.07-43.8 ± 3.46-53.6 ± 3.50-57.9 ± 3.45-51.7 ± 3.49
Change at Week 16-1.8 ± 2.87-58.0 ± 3.21-62.0 ± 3.21-68.3 ± 3.21-50.6 ± 3.17
Change at Week 201.2 ± 2.85-54.6 ± 3.32-62.0 ± 3.28-64.7 ± 3.28-49.1 ± 3.23
Change at Week 24-1.7 ± 3.07-51.5 ± 3.54-57.7 ± 3.49-64.1 ± 3.51-45.9 ± 3.52
Change at Week 283.5 ± 2.95-46.2 ± 3.41-55.7 ± 3.35-61.7 ± 3.38-63.4 ± 3.39
Change at Week 366.1 ± 4.66-44.7 ± 5.35-51.5 ± 5.25-54.9 ± 5.34-60.1 ± 5.32
Change at Week 48/ET1.7 ± 4.35-33.2 ± 4.96-42.8 ± 4.86-50.2 ± 4.94-55.0 ± 4.93
SecondaryPercent Change From Baseline at Week 24 in Apolipoprotein (Apo)C-III

LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · percentage change
Percent Change From Baseline at Week 24 in Apolipoprotein (Apo)C-III
percentage changePlaceboARO-APOC3 10 mg Q12WARO-APOC3 25 mg Q12WARO-APOC3 50 mg Q12WARO-APOC3 50 mg Q24W
Percent Change From Baseline at Week 24 in Apolipoprotein (Apo)C-III23.9 ± 21.90-58.9 ± 24.86-44.3 ± 24.54-65.7 ± 24.71-57.9 ± 24.70
SecondaryPercent Change From Baseline Over Time Through Week 48 in ApoC-III

LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 36, 48/ET
Reported as:
Least squares mean · percentage change
Percent Change From Baseline Over Time Through Week 48 in ApoC-III
percentage changePlaceboARO-APOC3 10 mg Q12WARO-APOC3 25 mg Q12WARO-APOC3 50 mg Q12WARO-APOC3 50 mg Q24W
Change at Week 419.3 ± 21.81-60.7 ± 24.78-69.7 ± 24.45-78.4 ± 24.66-82.7 ± 24.64
Change at Week 819.0 ± 21.84-57.3 ± 24.72-61.9 ± 24.48-71.8 ± 24.64-78.1 ± 24.62
Change at Week 1220.3 ± 21.90-48.7 ± 24.77-18.9 ± 24.57-59.2 ± 24.66-71.5 ± 24.68
Change at Week 1610.9 ± 21.92-69.9 ± 24.79-63.8 ± 24.54-78.9 ± 24.67-67.7 ± 24.62
Change at Week 2021.8 ± 21.88-64.0 ± 24.87-63.3 ± 24.58-69.3 ± 24.72-62.6 ± 24.65
Change at Week 2423.9 ± 21.90-58.9 ± 24.86-44.3 ± 24.54-65.7 ± 24.71-57.9 ± 24.70
Change at Week 2835.6 ± 21.90-51.7 ± 24.87-32.8 ± 24.55-53.3 ± 24.71-82.5 ± 24.70
Change at Week 3630.6 ± 21.96-46.3 ± 24.91-24.9 ± 24.58-34.5 ± 24.74-75.8 ± 24.70
Change at Week 48/ET27.3 ± 21.97-31.2 ± 24.97-13.9 ± 24.58-17.4 ± 24.78-64.8 ± 24.72
SecondaryPercent Change From Baseline at Week 24 in Fasting Non-High-Density Lipoprotein Cholesterol (Non-HDL-C)

LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · percentage change
Percent Change From Baseline at Week 24 in Fasting Non-High-Density Lipoprotein Cholesterol (Non-HDL-C)
percentage changePlaceboARO-APOC3 10 mg Q12WARO-APOC3 25 mg Q12WARO-APOC3 50 mg Q12WARO-APOC3 50 mg Q24W
Percent Change From Baseline at Week 24 in Fasting Non-High-Density Lipoprotein Cholesterol (Non-HDL-C)-2.7 ± 2.56-19.3 ± 2.93-20.1 ± 2.90-26.9 ± 2.92-10.3 ± 2.92
SecondaryPercent Change From Baseline Over Time Through Week 48 in Fasting Non-HDL-C

LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 36, 48/ET
Reported as:
Least squares mean · percentage change
Percent Change From Baseline Over Time Through Week 48 in Fasting Non-HDL-C
percentage changePlaceboARO-APOC3 10 mg Q12WARO-APOC3 25 mg Q12WARO-APOC3 50 mg Q12WARO-APOC3 50 mg Q24W
Change at Week 4-1.2 ± 2.19-17.3 ± 2.53-23.3 ± 2.48-26.3 ± 2.52-19.6 ± 2.53
Change at Week 8-1.0 ± 2.37-18.2 ± 2.69-22.4 ± 2.67-27.8 ± 2.70-16.2 ± 2.70
Change at Week 12-0.4 ± 2.65-15.5 ± 3.00-19.4 ± 3.01-21.9 ± 3.00-16.0 ± 3.02
Change at Week 16-1.4 ± 2.49-21.2 ± 2.80-23.8 ± 2.80-28.5 ± 2.81-15.5 ± 2.79
Change at Week 20-1.9 ± 2.82-20.9 ± 3.24-21.5 ± 3.21-27.3 ± 3.22-11.7 ± 3.20
Change at Week 24-2.7 ± 2.56-19.3 ± 2.93-20.1 ± 2.90-26.9 ± 2.92-10.3 ± 2.92
Change at Week 280.4 ± 2.91-17.1 ± 3.33-17.7 ± 3.29-25.6 ± 3.32-20.5 ± 3.33
Change at Week 360.0 ± 2.71-17.1 ± 3.09-17.1 ± 3.05-23.4 ± 3.10-17.3 ± 3.09
Change at Week 48/ET1.7 ± 2.96-12.1 ± 3.37-12.1 ± 3.29-21.8 ± 3.35-20.0 ± 3.35
SecondaryPercent Change From Baseline at Week 24 in Fasting High-Density Lipoprotein Cholesterol (HDL-C)

LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · percentage change
Percent Change From Baseline at Week 24 in Fasting High-Density Lipoprotein Cholesterol (HDL-C)
percentage changePlaceboARO-APOC3 10 mg Q12WARO-APOC3 25 mg Q12WARO-APOC3 50 mg Q12WARO-APOC3 50 mg Q24W
Percent Change From Baseline at Week 24 in Fasting High-Density Lipoprotein Cholesterol (HDL-C)4.7 ± 3.3437.9 ± 3.8146.8 ± 3.8250.5 ± 3.8032.8 ± 3.82
SecondaryPercent Change From Baseline Over Time Through Week 48 in Fasting HDL-C

LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 36, 48/ET
Reported as:
Least squares mean · percentage change
Percent Change From Baseline Over Time Through Week 48 in Fasting HDL-C
percentage changePlaceboARO-APOC3 10 mg Q12WARO-APOC3 25 mg Q12WARO-APOC3 50 mg Q12WARO-APOC3 50 mg Q24W
Change at Week 43.6 ± 3.3839.3 ± 3.8848.3 ± 3.8655.4 ± 3.8855.5 ± 3.90
Change at Week 82.0 ± 3.1832.1 ± 3.6146.4 ± 3.6354.3 ± 3.6252.8 ± 3.64
Change at Week 122.5 ± 3.1931.4 ± 3.6040.1 ± 3.6649.0 ± 3.6145.1 ± 3.65
Change at Week 163.2 ± 3.4645.8 ± 3.9056.4 ± 3.9364.2 ± 3.9141.6 ± 3.91
Change at Week 202.8 ± 3.2745.0 ± 3.7550.6 ± 3.7658.2 ± 3.7440.3 ± 3.73
Change at Week 244.7 ± 3.3437.9 ± 3.8146.8 ± 3.8250.5 ± 3.8032.8 ± 3.82
Change at Week 282.1 ± 3.4735.8 ± 3.9845.3 ± 3.9649.5 ± 3.9654.0 ± 3.99
Change at Week 361.6 ± 3.2530.8 ± 3.7237.0 ± 3.7143.1 ± 3.7249.7 ± 3.73
Change at Week 48/ET4.5 ± 3.5325.4 ± 4.0230.5 ± 3.9834.3 ± 4.0044.5 ± 4.01
SecondaryPercent Change From Baseline at Week 24 in Fasting Total Apolipoprotein B (ApoB)

LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · percentage change
Percent Change From Baseline at Week 24 in Fasting Total Apolipoprotein B (ApoB)
percentage changePlaceboARO-APOC3 10 mg Q12WARO-APOC3 25 mg Q12WARO-APOC3 50 mg Q12WARO-APOC3 50 mg Q24W
Percent Change From Baseline at Week 24 in Fasting Total Apolipoprotein B (ApoB)0.8 ± 2.57-9.5 ± 2.94-12.2 ± 2.89-18.3 ± 2.91-5.7 ± 2.91
SecondaryPercent Change From Baseline Over Time Through Week 48 in Fasting Total ApoB

LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 36, 48/ET
Reported as:
Least squares mean · percentage change
Percent Change From Baseline Over Time Through Week 48 in Fasting Total ApoB
percentage changePlaceboARO-APOC3 10 mg Q12WARO-APOC3 25 mg Q12WARO-APOC3 50 mg Q12WARO-APOC3 50 mg Q24W
Change at Week 4-1.3 ± 1.99-10.3 ± 2.30-15.5 ± 2.24-18.5 ± 2.28-13.5 ± 2.29
Change at Week 8-0.5 ± 2.26-11.0 ± 2.56-15.5 ± 2.54-20.3 ± 2.55-10.9 ± 2.56
Change at Week 120.9 ± 2.53-8.5 ± 2.87-14.3 ± 2.86-14.8 ± 2.85-10.8 ± 2.87
Change at Week 160.2 ± 2.30-12.8 ± 2.60-17.2 ± 2.57-20.6 ± 2.58-9.4 ± 2.58
Change at Week 200.5 ± 2.61-13.0 ± 3.00-14.3 ± 2.96-19.3 ± 2.97-7.3 ± 2.95
Change at Week 240.8 ± 2.57-9.5 ± 2.94-12.2 ± 2.89-18.3 ± 2.91-5.7 ± 2.91
Change at Week 285.1 ± 2.98-9.0 ± 3.41-10.0 ± 3.35-16.3 ± 3.38-12.1 ± 3.38
Change at Week 363.7 ± 2.68-7.8 ± 3.07-9.3 ± 3.00-15.4 ± 3.05-9.9 ± 3.04
Change at Week 48/ET3.3 ± 2.75-4.7 ± 3.14-6.4 ± 3.06-12.2 ± 3.11-11.9 ± 3.11
SecondaryPercent Change From Baseline at Week 24 in Fasting Low-Density Lipoprotein-Cholesterol (LDL-C)

LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · percentage change
Percent Change From Baseline at Week 24 in Fasting Low-Density Lipoprotein-Cholesterol (LDL-C)
percentage changePlaceboARO-APOC3 10 mg Q12WARO-APOC3 25 mg Q12WARO-APOC3 50 mg Q12WARO-APOC3 50 mg Q24W
Percent Change From Baseline at Week 24 in Fasting Low-Density Lipoprotein-Cholesterol (LDL-C)-0.1 ± 3.621.4 ± 4.143.9 ± 4.10-4.3 ± 4.137.3 ± 4.14
SecondaryPercent Change From Baseline Over Time Through Week 48 in Fasting LDL-C

LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 36, 48/ET
Reported as:
Least squares mean · percentage change
Percent Change From Baseline Over Time Through Week 48 in Fasting LDL-C
percentage changePlaceboARO-APOC3 10 mg Q12WARO-APOC3 25 mg Q12WARO-APOC3 50 mg Q12WARO-APOC3 50 mg Q24W
Change at Week 40.6 ± 3.185.0 ± 3.671.1 ± 3.590.4 ± 3.663.2 ± 3.67
Change at Week 81.7 ± 3.240.7 ± 3.680.6 ± 3.65-3.6 ± 3.697.4 ± 3.70
Change at Week 121.8 ± 3.682.5 ± 4.162.5 ± 4.181.6 ± 4.163.2 ± 4.20
Change at Week 161.5 ± 3.652.2 ± 4.110.4 ± 4.10-2.7 ± 4.113.2 ± 4.09
Change at Week 20-0.3 ± 3.781.3 ± 4.354.0 ± 4.31-3.9 ± 4.337.2 ± 4.30
Change at Week 24-0.1 ± 3.621.4 ± 4.143.9 ± 4.10-4.3 ± 4.137.3 ± 4.14
Change at Week 281.6 ± 3.860.2 ± 4.426.1 ± 4.37-3.6 ± 4.412.0 ± 4.42
Change at Week 361.6 ± 3.800.0 ± 4.335.3 ± 4.28-3.5 ± 4.355.7 ± 4.34
Change at Week 48/ET1.7 ± 3.882.0 ± 4.436.9 ± 4.32-4.0 ± 4.40-0.1 ± 4.40
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence, which did not necessarily have to have a causal relationship with this treatment. A serious AE (SAE) was an AE that: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of an existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; or was a medically important event or reaction. TEAEs were AEs that occurred following study drug administration or a pre-existing condition exacerbated following study drug administration.

Time frame:
Up to Week 48
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsPlaceboARO-APOC3 10 mg Q12WARO-APOC3 25 mg Q12WARO-APOC3 50 mg Q12WARO-APOC3 50 mg Q24W
All TEAEs5546454749
Treatment-related TEAEs879128
Serious TEAEs52575
TEAEs leading to study drug discontinuation20010
Deaths00121

Adverse events

Collected over Up to Week 48. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/87 (0%)5/87 (5.7%)55/87 (63.2%)
ARO-APOC3 10 mg Q12W0/67 (0%)2/67 (3%)47/67 (70.1%)
ARO-APOC3 25 mg Q12W1/67 (1.5%)5/67 (7.5%)44/67 (65.7%)
ARO-APOC3 50 mg Q12W2/66 (3%)7/66 (10.6%)48/66 (72.7%)
ARO-APOC3 50 mg Q24W1/66 (1.5%)5/66 (7.6%)48/66 (72.7%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventPlaceboARO-APOC3 10 mg Q12WARO-APOC3 25 mg Q12WARO-APOC3 50 mg Q12WARO-APOC3 50 mg Q24W
Aortic aneurysm ruptureVascular disorders0/870/670/670/661/66
Artery dissectionVascular disorders0/870/670/670/661/66
Multiple organ dysfunction syndromeGeneral disorders0/870/670/671/660/66
AsthmaRespiratory, thoracic and mediastinal disorders0/870/670/671/660/66
Completed suicidePsychiatric disorders0/870/670/671/660/66
Meniscus injuryInjury, poisoning and procedural complications0/870/670/671/660/66
Acute coronary syndromeCardiac disorders0/870/670/670/661/66
Myocardial infarctionCardiac disorders0/870/670/671/660/66
Myocardial ischaemiaCardiac disorders0/870/670/671/660/66
Coeliac artery aneurysmGastrointestinal disorders0/870/670/670/661/66
Most frequent other events
Showing 10 of 329
Most frequent other events
EventPlaceboARO-APOC3 10 mg Q12WARO-APOC3 25 mg Q12WARO-APOC3 50 mg Q12WARO-APOC3 50 mg Q24W
Type 2 diabetes mellitusMetabolism and nutrition disorders4/875/674/678/6611/66
COVID-19Infections and infestations12/878/6711/679/666/66
Upper respiratory tract infectionInfections and infestations7/873/677/672/669/66
Urinary tract infectionInfections and infestations7/874/676/676/662/66
HeadacheNervous system disorders3/872/673/674/665/66
BronchitisInfections and infestations1/874/672/673/665/66
Abdominal painGastrointestinal disorders0/870/670/674/661/66
ArthralgiaMusculoskeletal and connective tissue disorders3/870/671/672/664/66
Back painMusculoskeletal and connective tissue disorders2/872/672/674/660/66
CystitisInfections and infestations2/874/672/671/664/66

Baseline characteristics

Full Analysis Set: All randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)PlaceboARO-APOC3 10 mg Q12WARO-APOC3 25 mg Q12WARO-APOC3 50 mg Q12WARO-APOC3 50 mg Q24WTotal
Mean58.9 ± 9.7060.2 ± 11.7161.3 ± 11.2862.6 ± 10.5361.3 ± 11.8460.7 ± 10.99
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboARO-APOC3 10 mg Q12WARO-APOC3 25 mg Q12WARO-APOC3 50 mg Q12WARO-APOC3 50 mg Q24WTotal
Female4131302923154
Male4636373743199
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboARO-APOC3 10 mg Q12WARO-APOC3 25 mg Q12WARO-APOC3 50 mg Q12WARO-APOC3 50 mg Q24WTotal
Hispanic or Latino161812121573
Not Hispanic or Latino7149555351279
Unknown or Not Reported000101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboARO-APOC3 10 mg Q12WARO-APOC3 25 mg Q12WARO-APOC3 50 mg Q12WARO-APOC3 50 mg Q24WTotal
Race — White7962606362326
Race — Black or African American422008
Race — American Indian or Alaska Native001001
Race — Asian3231110
Race — Native Hawaiian or Other Pacific Islander001012
Race — Unknown000011
Race — Other110215
Mean Triglycerides (TG)
Mean Triglycerides (TG)(mg/deciliter (dL))PlaceboARO-APOC3 10 mg Q12WARO-APOC3 25 mg Q12WARO-APOC3 50 mg Q12WARO-APOC3 50 mg Q24WTotal
Mean237.22 ± 76.179253.15 ± 81.425234.08 ± 72.746250.25 ± 81.329248.01 ± 80.553244.10 ± 78.289
08

Study locations

30 sites
  • Research Site 3
    Beverly Hills, California 90211, United States
  • Research Site 8
    Northridge, California 91325, United States
  • Research Site 2
    Boca Raton, Florida 33434, United States
  • Research Site 1
    Fort Lauderdale, Florida 33308, United States
  • Research Site 14
    Miami Springs, Florida 33166, United States
  • Research Site 5
    Pembroke Pines, Florida 33024, United States
  • Research Site 18
    Dunwoody, Georgia 30338, United States
  • Research Site 31
    Las Vegas, Nevada 89121, United States
  • Research Site 17
    New Windsor, New York 12553, United States
  • Research Site 12
    Dayton, Ohio 45419, United States
  • Research Site 4
    Franklin, Ohio 45005, United States
  • Research Site 7
    Greenville, South Carolina 29607, United States
  • Research Site 6
    Houston, Texas 77002, United States
  • Research Site 32
    Houston, Texas 77030, United States
  • Research Site 13
    San Antonio, Texas 78249, United States
  • Research Site 30
    Morayfield, Queensland 4506, Australia
  • Research Site 29
    Adelaide, South Australia 5000, Australia
  • Research Site 19
    Clayton, Victoria 3168, Australia
  • Research Site 27
    Joondalup, Western Australia 6027, Australia
  • Research Site 15
    Concord, Ontario L4K 4M2, Canada
  • Research Site 10
    Montreal, Quebec H2W2T2, Canada
  • Research Site 20
    Balatonfüred, H-8230, Hungary
  • Research Site 21
    Debrecen, H-4032, Hungary
  • Research Site 22
    Nyíregyháza, H-4405, Hungary
  • Research Site 11
    Auckland, 2025, New Zealand
  • Research Site 16
    Christchurch, 8013, New Zealand
  • Research Site 28
    Lodz, 93-338, Poland
  • Research Site 24
    Lodz, 94-048, Poland
  • Research Site 25
    Poznan, 61-655, Poland
  • Research Site 26
    Rzeszów, 35-055, Poland
09

References and documents

Publications

  • Ballantyne CM, Vasas S, Azizad M, Clifton P, Rosenson RS, Chang T, Melquist S, Zhou R, Mushin M, Leeper NJ, Hellawell J, Gaudet D. Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia. N Engl J Med. 2024 Sep 12;391(10):899-912. doi: 10.1056/NEJMoa2404143. Epub 2024 May 28. PubMed 38804517 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Feb 2023, 16 months.

Results were first posted in Feb 2026, 3 years after primary completion. A results delay was requested in Feb 2024.

Of 35 industry-sponsored phase 2 interventional studies under Dyslipidemias, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 16 months is above that.

Counting every sponsor, half of 43 studies reached it within 13 months; a quarter within 7 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2021
First posted
Aug 10, 2021
StartActual
Sep 28, 2021
Primary completionActual
Feb 10, 2023
CompletionActual
Aug 14, 2023
Results delay requested
Feb 8, 2024
Results first posted
Feb 24, 2026
Last update
Apr 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04998201
Responsible party
Sponsor
First posted
Aug 10, 2021
Start date
Sep 28, 2021
Primary completion
Feb 10, 2023
Completion
Aug 14, 2023
Results posted
Feb 24, 2026
Last update
Apr 14, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Plozasiran

Start the discussion